SOLUBLE CTLA-4 MOLECULES AND DERIVATIVES THEREOF FOR TREATMENT OF MINIMAL CHANGE DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 26, 2014
filing date -
Jun 27, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
This disclosure relates to compositions and methods for treatment of minimal change disease. The compositions include soluble CTLA-4 molecules, and derivatives thereof, including belatacept and belatacept-like molecules that have been conjugated to a human immunoglobulin constant domain fragment.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully